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Background: Patients with Ewing sarcoma family of tumors (ESFT) who are resistant even to salvage chemotherapy,
have dismal prognoses and few therapeutic options. Because the docetaxel/irinotecan (DI) combination has not been
previously evaluated in ESFT, we prospectively evaluated its use in patients with recurrent or refractory ESFT.
Methods: Patients aged <30 years with ESFT, who failed≥ third-line therapy, were eligible. They received docetaxel
100 mg/m2 intravenously on day 1, and irinotecan 80 mg/m2 on days 1 and 8, of a 21-day cycle up to 15 cycles or until
disease progressed. The primary objective was objective response rate (ORR); secondary objectives were progression-free
survival (PFS) and safety.
Results: We enrolled nine patients (median age: 13 years); four were male. Two patients had recurrent disease and
seven had progressive disease. This group had undergone a median of four prior chemotherapy regimens (range: 3-6),
and received a total of 51 DI cycles (median: three cycles/per person; range: 1-15 cycles). The nine patients showed
one complete response (CR), two partial responses (PRs), one stable disease, and five progressive diseases, for an ORR
(CR + PR) of 3/9 (33.3%). Two patients with PR achieved CR with subsequent surgery. Overall median PFS was
2.2 months (range: 0.5-16.9 months). All nine patients had grade 4 neutropenia (100%); grade 3 diarrhea or grade 2/3
neuropathy each occurred in two patients (22%). All toxicities were manageable without serious morbidities or
treatment-related mortality.
Conclusions: The DI combination may be effective and tolerable for patients with heavily pre-treated ESFT.
Trial registration: NCT01380275. Registered June 21, 2011.
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The Ewing sarcoma family of tumors (ESFT) is the second
most common primary bone malignancy in children and
young adults [1]. It is a group of small, blue round cell neo-
plasms of neuroectodermal origin, which includes classical
Ewing sarcoma, primitive neuroectodermal tumors, and
Askin tumors of the chest wall [2]. With multimodality
treatment, the 5-year survival rate for locoregional ESFT is
60-75% depending on various series [3,4]. However, the
5-year survival rate for metastatic disease at diagnosis is* Correspondence: bkpark@ncc.re.kr
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unless otherwise stated.less than 30% [5], and for recurrent or refractory disease it
falls even below 20% [6].
As no standard salvage regimen exists for recurrent or
refractory ESFT, various regimens have been tried as
second-line agents, such as topotecan plus cyclophospha-
mide (TC), ifosfamide, carboplatin plus etoposide (ICE),
temozolomide plus irinotecan (TI), and gemcitabine plus
docetaxel (GD), yielding response rates varying between
29% and 66% [7-10]. However, many patients fail to re-
spond to these second-line agents, and chemotherapeutic
options are further limited when these agents also fail.
Furthermore, despite strenuous efforts, the survival rate
has not increased in patients with recurrent or refractorytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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need for more effective regimens.
Docetaxel is a semisynthetic taxane analog, which acts as
a mitotic spindle poison by promoting microtubule assem-
bly but inhibiting tubulin depolymerization, thus disrupting
cell division [11]. It has shown activity in patients with
many types of solid tumors, including ESFT [11]. Irinote-
can is a camptothecin prodrug that is metabolized by car-
boxylesterase to an active metabolite, SN-38 [12]. SN-38 is
a potent inhibitor of topoisomerase I, a critical enzyme in
DNA replication and transcription. Irinotecan has also
shown a significant activity in ESFT [12]. Docetaxel and
irinotecan (DI) have demonstrated additive and synergistic
activities in vitro and in vivo [13,14]. Additionally, they
have different biologic targets and mechanisms of resist-
ance from first-line and many second-line agents for ESFT.
Thus, DI may provide a suitable option in ESFT that shows
resistance to other regimens. However, the combination
has not been evaluated in ESFT to date.
Herein, we prospectively evaluated the efficacy and
toxicity profile of the DI combination in children and
young adults with recurrent or refractory ESFT. In this
report, we demonstrated that the combination is effect-
ive and tolerable in our heavily pre-treated cohort.
Methods
Patient eligibility
We recruited patients with histologically confirmed
ESFT who received DI chemotherapy at the National
Cancer Center, Korea, following relapse or progression
with ≥ third-line therapy. This study was originally de-
signed as a single-arm phase II trial to estimate the
complete response (CR) plus partial response (PR) rates,
with precision. Twenty-eight patients were required to
estimate the expected response rate of 25% with a 95%
confidence interval (CI) of ±15%. Assuming 20% follow-up
loss, the intended sample size required was 34. However,
because of slow recruitment caused by financial difficulties
on participants’ side, the recruitment was stopped prema-
turely after enrolling nine patients. Patients aged <30 years
with recurrent or refractory ESFT that was inoperable at
study entry, were eligible. Prior paclitaxel or topotecan use
was permitted, but prior therapy with docetaxel or irinote-
can at any time was not allowed. Patients with Karnofsky
(age >10 years) or Lansky (age ≤10 years) scores ≥50, and
measurable disease were eligible. ESFT was confirmed by a
single pathologist. For all nine tumor specimens, reverse
transcription-polymerase chain reaction and/or fluores-
cence in situ hybridization were conducted, revealing
EWS/Fli-1 translocation. Patients who had completed at
least one cycle of DI were evaluated for chemotherapy re-
sponse according to Response Evaluation Criteria in Solid
Tumors (RECIST). At the beginning of each cycle, patients
were required to have adequate hematologic values(absolute neutrophil count [ANC] ≥750/μL and platelet
count ≥75,000/μL), renal function (serum creatinine <1.5×
upper normal limit for age or creatinine clearance ≥60 mL/
min/1.73 m2), and liver function (total bilirubin ≤1.5 mg/
dL and AST/ALT levels <2.5× upper normal limits), and
no other non-hematologic toxicity of grade 2 or worse. Pa-
tients could not receive other anti-cancer or investigational
agents during the study period or within 4 weeks prior to
study entry. Patients who had been taking anticonvulsants
that might affect the metabolism of DI, who were pregnant
or lactating, had psychiatric disorders, uncontrolled infec-
tions, pre-existing neuropathy grade ≥2, or brain metasta-
ses were also excluded. Data were collected on gender, age,
sites of primary tumor and metastasis, previous surgery or
radiotherapy, previous chemotherapy regimens, date of the
last chemotherapy, date of DI commencement, perform-
ance status, number of cycles, best response, number of
admissions for toxicities and type of toxicities, date of pro-
gression, and date of death or the last follow-up.
All parents/guardians and/or patients gave informed
consent; the study was approved by the Institutional
Review Board of the National Cancer Center, Korea (IRB
number: NCCCTS-08-322) and complied with local laws
and regulations, and the Declaration of Helsinki.
Chemotherapeutic regimen
Docetaxel (Taxotere®; Sanofi-Aventis, Bridgewater, NJ,
USA) was administered as a 60-min intravenous (IV) infu-
sion at a dose of 100 mg/m2 followed by the administra-
tion of 80 mg/m2 irinotecan (Irinotecan®; Boryung
Pharmaceutical Co., Ltd, Seoul, Korea) IV over 90 min.
Docetaxel was given on day 1, and irinotecan on days 1
and 8 of a 21-day cycle. The cycles continued until pro-
gression of disease, the occurrence of unacceptable toxic-
ities, or patient withdrawal. The planned maximum
number of cycles was 12; however, two to three additional
cycles were given at the discretion of physicians when at
least partial response was maintained at the end of
12 cycles.
Patients were premedicated with antiemetic agents and
dexamethasone for a total of three doses. Atropine and
loperamide was used to treat early-onset (within 12 h after
irinotecan infusion) and delayed-onset diarrhea, respect-
ively, according to the reported guideline [15].
Irinotecan treatment on day 8 was delayed to day 10 if
grade ≥2 non-hematological toxicities, such as diarrhea,
occurred on the day when the dose was due. It was omit-
ted if grade ≥2 non-hematological toxicities continued to
day 10. If diarrhea of grade ≥3 persisted despite atropine
or loperamide use, the irinotecan dose in the next cycle
was reduced by 20%. Subsequent doses were further
reduced by 20% for recurrent toxicities.
Doses of docetaxel in the subsequent cycles were re-
duced by 20% if grade ≥2 neurotoxicity or recurrent fluid
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curred, including hepatotoxicity, myalgia, cardiac events,
or hypersensitivity. However, doses were not reduced for
grade 3 oral mucositis or infection. Subsequent doses were
further reduced by 20% for recurrent toxicities. Doses of
both docetaxel and irinotecan in subsequent cycles were
reduced by 20% if septicemia occurred. Granulocyte col-
ony stimulating factor (G-CSF) injections were initiated if
absolute neutrophil count (ANC) fell below 500/μL and
continued until ANC ≥1,000/μL. Dose re-escalation after
a dose reduction was not permitted for either docetaxel or
irinotecan. DI therapy was discontinued if grade 4 non-
hematological toxicities occurred.
Assessment of tumor response and toxicities
Tumor response was assessed by magnetic resonance im-
aging or computed tomography (CT) scanning, according
to RECIST criteria version 1.1 [16], at baseline and then
every two or three cycles. When clinically indicated, im-
ages were obtained earlier. We defined CR as a complete
regression of all apparent tumor masses and PR as >30%
decrease in the longest diameter of primary and/or meta-
static tumors with the absence of new lesions. Progressive
disease (PD) was defined as >20% increase in the longest
diameter of primary or metastatic tumors or the appear-
ance of new lesions. Stable disease (SD) was defined as the
absence of CR, PR, or PD. Either CR or PR was regarded
as an objective response (OR). When a patient was
deemed to have a CR, PR, or SD, tumor measurement was
repeated 4-6 weeks later to confirm the response. Images
were reviewed by a single radiologist who was blinded to
clinical information. Complete blood counts were ob-
tained on days 1 and 8 of each cycle, and serum chemistry
results were obtained on day 1.
Adverse events and laboratory variables were assessed
using the National Cancer Institute’s Common Termin-
ology Criteria for Adverse Events, version 4.0 (http://evs.
nci.nih.gov/).
Statistical analysis
The primary objective was the best OR rate (ORR), and
the secondary objectives were progression-free survival
(PFS) and toxicity profile.
Two parameters were used to evaluate efficacy, best
response over the entire duration of treatment, and PFS
(time between the first day of DI therapy and the date of
disease progression, death from any cause, or the last
follow-up). Differences in response rate were tested using
the Fisher’s exact test because of the small sample size.
The Kaplan-Meier method was used to estimate median
PFS; Greenwood’s formula was used to find its 95% CI.
The differences in survival were tested using the log rank
test. Two-sided P values were reported for all statistical
analyses. P <0.05 was considered significant. Statisticalanalyses were performed using STATA 12.0 for Windows
9 (StataCorp, College Station, TX, USA).
Results
Patient characteristics
Between July 2008 and January 2013, a total of 10 con-
secutive ESFT patients with relapsed or progressed disease
were treated at the Center for Pediatric Oncology of the
National Cancer Center, Korea. Of the 10 patients, one
was excluded because of an ineligible performance score.
The remaining nine all completed at least one cycle and
were analyzed for their DI responses and toxicities. Patient
characteristics at enrollment and their prior treatments
are shown in Table 1. Four (44%) of the nine patients were
male. Median age at study entry was 13 years (range: 5-21
years). The most common primary site (56%) was the
pelvic bone and/or pelvic cavity, including one at the lum-
bosacral spine with adjacent epidural sac and presacral
space. Five patients (56%) had metastatic diseases at initial
diagnosis. Eight (89%) had metastases at enrollment, most
commonly at the lungs (8/8, 100%) followed by the pleura
(5/8, 63%). The patients had undergone a median of four
previous chemotherapeutic regimens (range: 3-6) (Table 1).
Seven patients had undergone surgery for primary tumors,
but only two were left with negative resection margins; two
had inoperable primary sites. Three of the five patients
with lung metastases at initial diagnosis underwent wedge
resections of lung nodules, leaving negative resection mar-
gins of 1-2 mm. Eight of the nine patients had received
radiation therapy for primary and/or metastatic sites, and
five had undergone high-dose chemotherapy and autolo-
gous stem cell transplantation before enrollment.
Previous chemotherapeutic regimens delivered are sum-
marized in Table 2. Various chemotherapeutic or biological
agents had been used in the patients’ chemotherapy regi-
mens. Vincristine, ifosfamide, doxorubicin, and etoposide
with or without vincristine, actinomycin-D, and ifosfamide
had been used in five (56%) patients as a first-line agent.
As salvage regimens, TC with or without etoposide, and/or
carboplatin had been administered in 10 (36%) of total 28
regimens, and ICE with or without vincristine in seven reg-
imens. Actinomycin-D, cytarabine, paclitaxel, cisplatin, and
zoledronate had also been used in various combinations.
Unique patient number (UPN) 1 had received an insulin-
like growth factor-1 receptor antibody after disease pro-
gression without effect. As conditioning regimens delivered
before stem cell transplantation, busulfan/melphalan had
been used in two patients and melphalan/etoposide- based
regimens in the others (Table 2).
Tumor response
Reasons for DI therapy, number of DI cycles administered,
DI response, and treatment outcomes are described in
Table 3. At the time of study entry, seven patients had
Table 1 Patient characteristics and their previous therapies at enrollment (n = 9)










1 Lt ilium Lungs, pleura,
LS spines, Rt femur, and tibia
Lungs, pleura 6 Resection of pelvic






Lungs Lungs, pleura 4 Resection of
mediastinal and






None PS, lungs, LS
spines with
epidural sac






None PS 5 No No No
5 Lt chest wall
and ribs
Lungs, pleura PS, lungs,
pleura, brain,
liver, kidney




























None PS, lungs 3 No Yes Yes
9 Lt Humerus None Lungs, pleura 3 Resection of humeral
mass (NM)
Yes Yes
ASCT, autologous stem cell transplantation; HDC, high-dose chemotherapy; L, lumbar; L/Ns, lymph nodes; LS, lumbosacral; Lt, left; NM, negative margin; PM,
positive margin; PS, primary site; Rt, right; UPN, unique patient number.
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relapse; and one experienced a third relapse. The patients
received a median of three DI cycles (range: 1-15). Two
patients received only one cycle each, owing to overt dis-
ease progression. Three experienced progression after two
or three cycles. One (UPN 8) showed SD after two cycles,
but PD after four cycles, and the SD was not confirmed in
repeat imaging. The remaining three patients reported re-
sponses. One (UPN 1) had a CR (Figure 1) after five cycles
and received nine more cycles (14 cycles in all). Unfortu-
nately, he developed a lung relapse 2 months after com-
pleting the DI regimen. Another two patients (UPNs 6
and 9) had PRs (Figure 1) after five and three cycles,
respectively, which rendered their lung lesions resectable,
and underwent excision of pulmonary metastases after
eight and three cycles, respectively, which resulted in CR.
Pathology revealed metastatic ESFT. After surgery, UPN 6
continued to have DI and received 15 cycles in total, but
developed lung relapse 4 months post-DI therapy. UPN 9
received nine cycles in total, and remained in CR while on
therapy (as of analysis on July 31, 2013). No response was
observed in the five patients who had primary refractorydisease (no previous CR), while three of the four patients
with secondary refractory disease (presence of previous
CR with subsequent refractoriness) or relapse responded
to DI (P = 0.048 with Fisher’s exact test). Moreover, all
three responders had isolated lung and pleural lesions as
metastatic sites on enrollment (Table 1).
In the entire cohort, 1 CR and 2 PRs were obtained,
for an ORR of 33% (3/9) (95% CI, 7.5-70.1).Survival results
At the time of our analysis, seven patients (78%) had died
of disease progression, and two (22%) were alive (Table 3).
Metastatic tumors in the two surviving patients shrunk
enough for them to undergo metastatectomy with DI ther-
apy, leaving negative resection margins of 5 mm (UPN 6)
and 7 mm (UPN 9). The median follow-up period was
6.4 months (range: 1.0-41.3 months). The median PFS of
the cohort was 2.2 months (range: 0.5-16.9 months), and
the estimated 6- and 12-month PFS rates were 33.3 ±
15.7% (mean ± SD) for each (Figure 2A). Outcome was bet-
ter in patients with secondary PD or relapse compared
Table 2 Previous chemotherapeutic regimens
administered before study enrollment
Regimens Number (%)
First-line chemotherapy n = 9
VIDE with or without VAI regimen 5 (56)
VDC/IE regimen 3 (33)
ICE 1 (11)
Salvage chemo and/or biotherapy n = 28
TC with or without etoposide and/or carboplatin 10 (36)
ICE or VICE 7 (25)
VAC 2 (7)
Others* 9 (32)





*Cytarabine, paclitaxel, cisplatin, and zoledronate were used in
various combinations.
Abbreviations: ASCT, autologous stem cell transplantation; BuMel, busulfan/
melphalan; ICE, ifosfamide/carboplatin/etoposide; MEC, melphalan/etoposide/
carboplatin; MET, melphalan/etoposide/thiotepa; METBI, melphalan/etoposide/
total body irradiation; TC, topotecan/cyclophosphamide; VAC, vincristine/
actinomycin-D/cyclophosphamide; VAI, vincristine/actinomycin-D/ifosfamide;
VDC/IE, vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/
etoposide; VICE, vincristine/ifosfamide/carboplatin/etoposide;
VIDE, vincristine/ifosfamide/doxorubicin/etoposide.
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12.4 months; P = 0.018 [log-rank test]) (Figure 2B).
Toxicities
All patients were evaluable for toxicities (Table 4). The
cohort received a total of 51 DI cycles.
Principal toxic effects were hematologic and gastrointes-
tinal. All patients experienced grade 4 neutropenia afterTable 3 Reason for DI therapy, number of DI cycles, DI respon
UPN Reason for DI
therapy




1 SPD 14 Completed
2 2nd relapse 3 Stopped
3 PPD 1 Stopped
4 PPD 2 Stopped
5 PPD 1 Stopped
6 SPD 15 Completed
7 PPD 2 Stopped
8 PPD 4 Stopped
9 3rd relapse 9 Ongoing
*Two patients achieved PR with DI chemotherapy, followed by CR with subsequent
†SD was not confirmed in repeat imaging.
Abbreviations: AWD, alive with disease; CR, complete response; DI, docetaxel and iri
disease; PFS, progression-free survival; PPD, primary progressive disease; PR, partial
patient number.each cycle, which lasted for a median of 5 days per cycle
(range: 2-11 days). Six episodes (6/51, 12%) of grade 3
neutropenic fever occurred in five patients (5/9, 56%), but
no single episode of septicemia occurred. One patient
(UPN 6) suffered from an orbital cellulitis, and another
patient (UPN 5) developed an anal abscess with growth of
K. pneumonia. Both of these infections were controlled by
IV antibiotics without further complications. Grade 3/4
anemia and thrombocytopenia occurred in 17 (34%) and
11 (22%) cycles, respectively, without provoking any sig-
nificant cardiopulmonary symptoms or bleeding. As for
non-hematologic toxicities, no nausea or vomiting of
grade ≥3 occurred. Although grade 2 diarrhea occurred in
17 cycles (33%), grade 3 diarrhea occurred only in two
cycles (4%). Grade 2 fluid retention, including pleural effu-
sion, pericardial effusion, or edema, which occurred after
the fifth and ninth cycle in two patients (UPNs 1 and 6,
respectively), was managed with dexamethasone and
diuretics, resulting in partial resolution with no further ag-
gravation. Two patients (UPNs 1 and 6) developed grade
2/3 peripheral neuropathy in 15 cycles (29%), which was
controlled with gabapentin with or without amitriptyline.
Only one chemotherapy cycle was delayed longer than
2 weeks, in UPN 6 owing to orbital cellulitis. Dose reduction
of docetaxel by 20% was required in two patients because of
grade 2/3 neurotoxicity and grade 2 fluid retention. Dose
reduction of irinotecan by 20% was required in two patients
because of grade 3 diarrhea. Although five patients were
hospitalized, for a total of eight times, for neutropenic fever
(6/8, 75%), diarrhea, or oral mucositis, they fully recovered
from these events. No treatment-related mortality occurred
during the study period.
Discussion
This study, to the best of our knowledge, is the first to







CR DOD 12.4 17.1
PD DOD 2.2 24.6
PD DOD 0.5 1.5
PD DOD 1.4 1.9
PD DOD 0.5 1
PR* AWD 16.9 41.3
PD DOD 1.4 6.2
SD† DOD 3.1 10.1
PR* NED 6.4 6.4
resection of pulmonary metastases.
notecan; DOD, died of disease; NED, no evidence of disease; PD, progressive




(UPN 6) (UPN 9)
Figure 1 Computed tomography chest scans of three patients, showing response to docetaxel and irinotecan (DI) combination. No
lung lesion was visible (complete response) after five cycles of DI in unique patient number (UPN) 1. UPNs 6 and 9 showed decreases in tumor
(arrow) measurements of 40% after five cycles and 50% after three cycles, respectively, indicating partial responses by Response Evaluation Criteria
in Solid Tumors (RECIST) version 1.1.
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ORR is notable considering that all patients in our study
were heavily pre-treated and had received three or more
chemotherapy regimens. Previous studies of recurrent
and/or refractory ESFT have documented that the ORR
to various salvage regimens has a range of 29-66%. The
reported response rate in this study is comparable to or
lower than those achieved by TC (33-35%), ICE (48%),
TI (29-63%), or GD (66%) [7-10,17,18]. However, these
regimens have been used mostly in the second- or third-
line settings, whereas our DI chemotherapy was used asA
Figure 2 Progression-free survival (PFS). (A) Kaplan-Meier estimation of
patients with primary progressive disease (PPD) and four with secondary pa ≥ fourth-line agent. In addition, ICE and TC had been
already attempted in seven or eight patients before study
entry, suggesting the usefulness of DI even in ESFT cases
that fail commonly used salvage regimens. In one report,
four of the six patients responded to GD; however, these
patients reportedly had undergone only up to three pre-
vious regimens [10]. Although a high 63% response rate
was reported in 19 patients with recurrent/progressive
ESFT treated with TI [17], it was conducted mostly in
the second-line setting. In comparison, in another study
of the efficacy of TI in 14 patients with recurrent/B
PFS of all nine patients; and (B) difference in median PFS between five
rogressive disease (SPD) or relapse (P = 0.018).
Table 4 Toxicity profile* in nine eligible patients who received a total of 51 cycles
















Anemia 27 (53) 6 (67) 12 (24) 7 (78) 5 (10) 2 (22) 7 (78)
Thrombocytopenia 5 (10) 4 (44) 7 (14) 3 (33) 4 (8) 3 (33) 6 (67)
Leucopenia - - 2 (4) 1 (11) 49 (96) 8 (89) 9 (100)
Neutropenia - - - - 51 (100) 9 (100) 9 (100)
Neutropenic fever - - 6 (12) 5 (56) - - 5 (56)
Eye infection - - 1 (2) 1 (11) - - 1 (11)
Nail infection 1 (2) 1 (11) - - - - -
Anorectal infection - - 1 (2) 1 (11) - - 1 (11)
Non-hematologic
Headache 1 (2) 1 (11) -
Dysgeusia 1 (2) 1 (11) - - - - -
Oral mucositis 5 (10) 4 (44) 2 (4) 1 (11) - - 1 (11)
Nausea 4 (8) 2 (22) - - - - -
Vomiting 9 (18) 6 (67) - - - - -
Abdominal pain 6 (12) 3 (33) - - - - -
Diarrhea 17 (33) 5 (56) 2 (4) 2 (22) - - 2 (22)
Chest discomfort 1 (2) 1 (11) - - - - -
Pleural effusion 3 (6) 2 (22) - - - - -
Pericardial effusion 1 (2) 1 (11) - - - - -
Edema 1 (2) 1 (11) - - - - -
Peripheral
neuropathy
6 (12) 2 (22) 9 (18) 1 (11) - - 1 (11)
Tremor 1 (2) 1 (11) - - - - -
Muscle weakness 1 (2) 1 (11) 14 (27) 1 (11) - - 1 (11)
*If a patient suffered from toxicity of more than one grade, each grade was counted separately.
Abbreviations: -, none.
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treated, ORR declined to 29% [9]; the clinical status of
these 14 patients (when TI was started) was first relapse
in six patients and second or further relapse in eight
patients, which indicates that our cohort was even more
heavily pre-treated. In fact, our cohort was characterized
by one of the highest representation of heavily pre-
treated patients, which is associated with likely resist-
ance to multiple chemotherapeutic agents.
Phase II trials of DI, using 1- or 3- week dosing sched-
ules, have been conducted in various adult solid tumors,
including esophageal, gastric, and non-small cell lung
cancers [19-21]. A study of adult patients with advanced
gastric cancer showed a 60% ORR, with the starting dose
of irinotecan 160 mg/m2 and docetaxel 65 mg/m2 every
3 weeks [20]. However, dose reductions (irinotecan to
120 mg/m2 and docetaxel to 50 mg/m2) because of tox-
icity reduced the response rate to 10.3%, indicating that
the higher dose is critical for response rate. A phase Istudy has shown that, with filgrastim support, docetaxel
dose at 100-185 mg/m2 every 3 weeks can be used for
phase II trials of children with refractory solid tumors
[22]. We thus used an intensified irinotecan dose of
160 mg/m2 (80 mg/m2 on days 1 and 8 per cycle) and a
docetaxel dose of 100 mg/m2, considering an otherwise
dismal outcome of our series. Although docetaxel admin-
istered on a weekly basis is known to be less myelosup-
pressive [23], we administered docetaxel every 3 weeks to
reduce cost without causing decreased efficacy [24]. Simi-
larly, weekly irinotecan dosing was used because of a
limited free drug supply, although protracted dosing
schedules are commonly used in pediatric trials [9,18].
Although the three patients who achieved CR with DI
chemotherapy with or without surgery reflect encouraging
results, considering the heavily pretreated status of our co-
hort, the duration of remission did not last long (median
CR duration: 8.9 months; range: 4.4-10.6 months). Simi-
larly, a very recent report on the use of vincristine,
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therapy in patients with relapsed or refractory Ewing
sarcoma showed that despite the high ORR of 54%, only
22% of patients were alive after a median follow-up of
10.3 months [18]. Hence, approaches to maintain a durable
remission, such as maintenance therapy, are required. To
this end, biological agents might be an option because less
toxic agents are desirable in the heavily pre-treated setting.
Although the small cohort size precluded analysis of
factors related to DI response, two important findings
warrant attention. First, all patients who responded to
DI had isolated pulmonary lesions at protocol entry. In
accordance with this finding, post-recurrence survival
advantage has been shown in ESFT patients with iso-
lated pulmonary recurrences [25]. Of the three DI-
responsive patients, two patients with PR survived while
the patient with CR did not. The two surviving patients
underwent metastatectomy for their shrunken pulmon-
ary metastases with DI therapy, but the non-surviving
patient did not do so before complete resolution of his
pulmonary disease because he had a previous pulmonary
metastatectomy. Second, no patients with primary PD
responded, which implies inherent chemoresistance. In
addition to these findings, although the small sample size
precluded statistical analysis of the possible relationship
between patients’ number of previous chemotherapeutic
regimens versus DI response or PFS, the subgroup with
four or more previous regimens reported 1/5 (20%)
response and median PFS of 1.4 months (range: 0.5-
12.4 months), compared with the subgroup with less than
four previous regimens who reported 2/4 (50%) response
and median PFS of 4.8 months (range: 1.4-16.9 months).
With regard to hematologic toxicities, grade 3/4 leuco-
penia or neutropenia occurred in all patients, and grade 3/4
anemia and thrombocytopenia in seven and six patients,
respectively (Table 4). Myelosuppression is a major toxicity
of docetaxel given in a 3-weekly schedule [11]. Irinotecan is
also known to be moderately myelotoxic, especially with
regard to neutropenia [15]. Therefore, the association of DI
with high incidence of grade 3/4 hematologic toxicities in
our series was not surprising. Neutropenic fever, which
occurred in six (12%) of the 51 cycles, was accompanied by
one grade 3 orbital cellulitis and another grade 3 anorectal
abscess, but these infections were effectively managed
without further morbidity. In addition, no single episode of
septicemia happened. Even the five patients who had re-
ceived previous high-dose chemotherapy and hematopoie-
tic stem cell transplants tolerated DI therapy well. Of the
non-hematologic toxicities, grade 2 fluid retention, grade 2/
3 neurotoxicity, and grade 3 diarrhea resulted in dose re-
duction of docetaxel or irinotecan; however, these toxicities
were manageable with supportive care alone.
Despite the use of intensified dosage, both docetaxel and
irinotecan required one dose-level reduction in twopatients for each. Chemotherapy schedule was delayed in
only one patient. Moreover, all toxicities were manageable
and no treatment-related mortality occurred. These results
indicate that DI therapy was relatively safe in our series.
This study had several limitations. First, our cohort size
was small, although the patients suffered from uniform
pathology, unlike many other trials of pediatric sarcomas
with various histologies [8,10]. Second, docetaxel was ad-
ministered every 3 weeks instead of weekly in an attempt
to reduce cost, which may have resulted in enhanced
myelotoxicity.
This study was the first to show the usefulness of the DI
combination in patients with ESFT, and is characterized
by one of the highest representations of heavily pre-
treated patients reported so far. Testing this combination
at earlier stage of disease, such as first relapse, could be in-
teresting. Moreover, because of the short remission period
with unsatisfactory PFS even in patients who achieve CR,
the benefit of adjunct treatments, such as biological
agents, in combination with or following DI therapy,
warrants evaluation.
Conclusions
This prospective study suggests that docetaxel in combin-
ation with irinotecan shows an encouraging antitumor
efficacy with a manageable toxicity profile in children and
young adults with recurrent and/or refractory ESFT, who
have been heavily pre-treated. However, this finding
should be verified in a larger cohort.
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